Long-term treatment with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a comparative, real-world cohort study.

ABSTRACT:

Rationale

Limited data exists on the long-term comparative efficacy and tolerability of pirfenidone and nintedanib, the two approved treatments for idiopathic pulmonary fibrosis (IPF).

Methods

We retrospectively enrolled IPF patients treated with either pirfenidone or nintedanib at our centre between 2017 and 2023. Progression-free survival (PFS), defined as time to death or ≥ 10% decline in % predicted forced vital capacity (FVC) and continuous FVC decline were compared between groups defined by antifibrotic type or treatment intensity (full or reduced). Time to drug dose reduction was also compared. Statistical analysis included Kaplan-Meier curves with Log-Rank tests, Cox proportional hazards models and linear mixed-effects models.

Results

A total of 292 IPF patien

SUBMITTER: Lalla F 

PROVIDER: S-EPMC12506389 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature